Clinical economics review: irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The ubiquitous nature of irritable bowel syndrome (IBS), coupled with a lack of good treatment options, has created the impression that the condition must represent a large drain on health‐care resources. The literature certainly appears to support this view but is largely based on patients seen in referral centres (10–15%) and it may not be appropriate to extrapolate these data to the IBS population as a whole (85–90%). In addition to reviewing such literature that exists on the economics of IBS, this paper contains some new data, which suggest that the direct costs of the condition, certainly in the UK, may not be quite as high as has previously been assumed. This may be partly due to factors such as the low cost of the drugs used to treat the condition and the tendency for many patients to stop consulting because of disenchantment with the inadequacies of current therapy. Conversely, the indirect and intangible costs of the disorder appear to be much greater, but these burdens obviously do not have such an impact on those responsible for purchasing and providing health care for IBS sufferers. Paradoxically, if a new, effective therapy for IBS were forthcoming, the situation could change dramatically, especially if it involved a new drug. Any such agent would inevitably be more expensive than anything available today, leading to a potentially dramatic escalation in the direct costs of this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Epidemiology of colonic symptoms and the irritable bowel syndrome
Talley, N. J., Zinsmeister, A. R., van Dyke, C., & Melton, L. J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90717-y · Cited by 648
Medical costs in community subjects with irritable bowel syndrome
Talley, N. J., Gabriel, S. E., Harmsen, W. S., Zinsmeister, A. R., & Evans, R. W. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90738-6 · Cited by 460
Symptom complaints and health care seeking behavior in subjects with bowel dysfunction
Sandler, R. S., Drossman, D. A., Nathan, H. P., & McKee, D. C. (1984) · Gastroenterology · doi:10.1016/0016-5085(84)90706-6 · Cited by 326
Walker, E. A., Katon, W. J., Jemelka, R. P., & Roy-Byrne, P. P. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90133-v · Cited by 195
Cited by
Postinfectious Irritable Bowel Syndrome
Spiller, R., & Garsed, K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.074 · Cited by 1,024
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 997
Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
Self-citationThe impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781
Camilleri, M., Northcutt, A. R., Kong, S., Dukes, G. E., McSorley, D., & Mangel, A. W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02033-x · Cited by 556
Metadata
- Authors
- WELLS, N. E. J., HAHN, B. A., & WHORWELL, P. J.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1997-11
- Volume
- 11
- Issue
- 6
- Pages
- 1019-1030
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2140517758
- Cited by
- 109
- References
- 5
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical economics review: irritable bowel syndrome. https://app.cochat.ai/papers/10.1046/j.1365-2036.1997.00262.x
- The paper
- WELLS, N. E. J., HAHN, B. A., & WHORWELL, P. J. (1997). Clinical economics review: irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.1997.00262.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.